Complexin 2 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Complexin-2 (CPLX2) is a 129-amino acid soluble protein that regulates synaptic vesicle fusion by binding to the SNARE complex. It modulates both spontaneous and evoked neurotransmitter release.
| Attribute |
Value |
| Protein Name |
Complexin-2 |
| Gene |
CPLX2 |
| UniProt ID |
O75178 |
| PDB ID |
1GID, 2N0P |
| Molecular Weight |
14.5 kDa |
| Subcellular Localization |
Cytosolic (presynaptic terminal) |
| Protein Family |
Complexin family (CPLX1-4) |
Complexin-2 contains:
- N-terminal domain: Binds to assembled SNARE complexes
- Central α-helical domain: The spine that interacts with SNARE bundle
- C-terminal domain: Membrane attachment via hydrophobic interactions
Complexin-2 regulates neurotransmitter release:
- SNARE Binding: Binds to assembled SNARE complexes
- Release Modulation: Facilitates both spontaneous and evoked release
- Fusion Clamp: Prevents premature fusion while vesicles are docked
- Synaptic Plasticity: Regulates short-term plasticity (facilitation/depression)
- Neuroprotection: Has neuroprotective roles in various models
- CPLX2 levels reduced in hippocampus in AD
- Involved in Aβ-induced synaptic dysfunction
- May contribute to memory impairment
- Altered SNARE regulation affects dopaminergic transmission
- CPLX2 may protect against degeneration
- Mutations affect release probability and seizure threshold
- CPLX2 dysregulation in epileptic tissue
- CPLX2 expression altered in prefrontal cortex
- Associated deficits
- Mutant huntingtin affects complexin function
- Contributes to synaptic dysfunction
| Approach |
Target |
Status |
| Small molecule modulators |
CPLX2-SNARE interaction |
Research |
| Gene therapy |
AAV-CPLX2 for neuroprotection |
Preclinical |
- Complexin structure and function - Nat Struct Biol (2001) - PMID:11354656
- CPLX2 in Alzheimer's disease - J Neurosci (2009) - PMID:19244523
- Complexin and synaptic plasticity - Neuron (2012) - PMID:22958824
- CPLX2 in Huntington's disease - Proc Natl Acad Sci (2014) - PMID:25278599
The study of Complexin 2 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- McMahon HE, et al. (1995). 'Complexins: cytosolic proteins that regulate SNARE-mediated fusion.' Nature. PMID:7611395
- Giraud P, et al. (1998). 'Complexin and synaptic vesicle exocytosis.' Science. PMID:9729987
- Rosenmund C, et al. (2003). 'Regulation of neurotransmitter release by complexin.' Nature Neuroscience. PMID:14503283
- Liu J, et al. (2019). 'Complexin function in synaptic transmission.' Cell. PMID:31150673
- Dhara M, et al. (2018). 'Complexin stabilizes partially zipped SNARE complexes.' Proceedings of the National Academy of Sciences. PMID:29367403
- Bera S, et al. (2021). 'Complexin mutations and neurodegenerative disease.' Human Molecular Genetics. PMID:33444155
- Cho RW, et al. (2010). 'Complexin and spontaneous release.' Journal of Physiology. PMID:20157055
- Rizo J, et al. (2018). 'Molecular mechanisms underlying neurotransmitter release.' Annual Review of Biophysics. PMID:29689794
Complexin-2 has been implicated in several neurological conditions:
- Alzheimer's Disease: CPLX2 levels are reduced in AD brains, correlating with cognitive decline. The protein plays a protective role against amyloid-beta-induced synaptic toxicity.
- Parkinson's Disease: Altered complexin-2 function affects dopaminergic synaptic vesicle release, contributing to motor deficits.
- Schizophrenia: CPLX2 expression is downregulated in schizophrenic brains, affecting inhibitory synapse function.
- Huntington's Disease: Mutant huntingtin disrupts complexin-2 function, impairing synaptic vesicle priming.
Targeting complexin-2 may offer therapeutic benefits:
- Synaptic Stabilizers: Compounds that enhance complexin-2 function could protect against synaptic loss in neurodegeneration.
- Gene Therapy: AAV-mediated CPLX2 delivery shows promise in preclinical models.
- SNARE Complex Modulators: Understanding complexin-SNARE interactions enables targeted drug development.
Current research areas include:
- Structure-function studies of complexin domains
- Development of small molecules targeting complexin-SNARE interactions
- Investigation of complexin-1 vs complexin-2 functional differences
- Role in asynchronous neurotransmitter release
- CPLX2 Knockout Mice: Viable but show enhanced spontaneous release and impaired synchrony.
- Double KO (CPLX1/2): Severe deficits in synchronous release.
- Transgenic overexpression: Enhanced synaptic plasticity and memory.